Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry
Year: 2026
Type: article
Abstract: BACKGROUND/OBJECTIVE: The multifactorial disease burden of moderate-to-severe atopic dermatitis (AD) may affect children's growth. We report height, weight, and body mass index (BMI) of children under 12 years old with moderate-to-severe AD in comparison to the general population. METHODS: This was a cross-sectional analysis of enrollment data from PEDISTAD, a global real-world observational study of pediatric patients < 12 years old with moderate-to-severe AD. RESULTS: Among the 1329 children with moderate-to-severe AD, 72% of male children 5 to < 12 years were below the 50th percentile for height, as were 53% of females in this age group. In contrast, the weight of children 5 to < 12 years was above the 50th percentile in 56% of males and 52% of females, resulting in above-average BMI values. In the 0 to < 5 years old age groups, height and weight were above the 50th percentile for 59% and 50% of female children, and 52% and 42% of male children, respectively. CONCLUSIONS: This real-world observational study showed in children 5 to < 12 years old with moderate-to-severe AD that the average height was lower than the US 50th percentile, with a more pronounced reduction in male children. Additionally, higher weight and, as a result, higher BMI were observed in the children included in this analysis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03687359.
Source: Pediatric Dermatology
DOI: 10.1111/pde.70335
Institutions: Northwestern University, Trinity College Dublin, Hospital Sant Joan de Déu Barcelona, University Medical Center Utrecht, Cardinal Glennon Children’s Medical Center, Saint Louis University, Sheffield Children's Hospital, University of Sheffield, University of Calgary, Alberta Children's Hospital, University of California San Diego, Rady Children's Hospital-San Diego, Regeneron (United States)
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,920
Funders: Sanofi, Regeneron Pharmaceuticals
Award: G3199644471
OpenAlex ID: W7203686845
